Abstract Library

#4617 Analysis of new immunohistochemical biomarkers in a cohort of pancreatic NETs

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are rare diseases with a 10-year survival rate of only 40-50%. The ATRX, DAXX and ARX, PDX1 expressions in PanNETs were considered poor prognostic factors in some studies, but inconsistent in others.

Conference:

Presenting Author:

Authors: Ciobanu O, Martin S, Herlea V, Vasilescu F, Balaban D,

Keywords: Pancreatic neuroendocrine tumour, ATRX, DAXX, ARX, PDX1,

#3742 Pancreatic neuroendocrine neoplasms – Epidemiological description, clinical and pathological aspects

Introduction: Pancreatic neuroendocrine neoplasms (PanNENs) are considered among the most aggressive, therefore an early diagnosis and proper management are major challenges globally. The incidence of PanNENs is rising as well as the unmet need to study their epidemiology.

Conference:

Presenting Author: Ciobanu O

Authors: Martin S, Ciobanu O, Herlea V, Fica S,

Keywords: pancreatic neuroendocrine neoplasm, epidemiology, clinical features, pathological aspects,

#1782 Small Cell Metastatic Ascending Colon Neuroendocrine Carcinoma

Introduction: Poorly differentiated neuroendocrine carcinoma (NEC) of the gastrointestinal tract are rare malignant tumors with a poor prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Croitoru A

Authors: Croitoru A, Dinu I, Herlea V, Becheanu G, Dima S,

Keywords: Chemotherapy, metastases,

#1779 Large Cell Metastatic Pancreatic Neuroendocrine Carcinoma Treated with Somatostatin Analogues

Introduction: Poorly differentiated neuroendocrine carcinoma of the pancreas are rare malignant tumors with a poor prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Croitoru A

Authors: Croitoru A, Dinu I, Herlea V, Becheanu G, Grasu M,

Keywords: carcinoid syndrome, somatostatin analogues,